Home > Hematologics Salary

Hematologics Salary

  • 45
  • 27
  • 41
Hematologics average salary is $106,400, median salary is $110,000 with a salary range from $79,200 to $130,000.
Hematologics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Hematologics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 3 Hematologics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Senior Portfolio Strategist 130,000-130,000 San Francisco, CA, 94101 2016 Hematologics Senior Portfolio Strategist Salaries (2)
Hematologics San Francisco, CA Salaries
Senior Portfolio Strategist 110,000-110,000 San Francisco, CA, 94101 2014 Hematologics Senior Portfolio Strategist Salaries (2)
Hematologics San Francisco, CA Salaries
Associate, Client Service & Operations 79,200-79,200 San Francisco, CA, 94101 2014 Hematologics Associate, Client Service & Operations Salaries (1)
Hematologics San Francisco, CA Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Hematologics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Hematologics Jobs
See more Hematologics Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Hematologics... Information
  • Hematologics Inc
  • Industry: Other
  • City: Seattle, WA
  • HematoLogics , Incorporated is a group of scientists and physicians who are committed to propelling flow cytometry and immunofluorescence techniques to their highest potential for prognosis and diagnosis in hematopathologic malignancies. Scientists at HematoLogics pioneered the concept of abnormal antigen expression as a tumor specific marker of neoplasia, an approach which has taken flow cytometry from a "useful" test in determining lineage of leukemia, to a primary procedure in diagnosis and patient monitoring. As we have validated in numerous publications over the last 15 years, this process allows for detection of aberrant cells often not anticipated in the initial